Latest Cytokinetics Incorporated Stories
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure.
Cytokinetics Receives Exercise Fee of $50 Million Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc.
- GlaxoSmithKline continues to lead development activities for GSK-923295 LONDON, Dec.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present corporate updates at two investor conferences in November: Mr.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented during a Special Program at the 2008 Scientific Sessions of the American Heart Association which is being held November 8-12, 2008 at the Ernest N.
Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2008 at 4:00 p.m. Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 p.m.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), and one poster containing data on SB-743921, an inhibitor of kinesin spindle protein (KSP), were presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held at the Geneva Palexpo, Geneva, Switzerland.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 were presented during a Special Program at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society, which was held October 16-18, 2008 at the Hotel Pacific Tokyo in Tokyo, Japan.
- The act of sweetening by admixture of some saccharine substance.